PreprintPDF Available

MANAGEMENT OF THE PATIENT WITH PERSISTENT SYMPTOMS OF COVID (for Chronic COVID or Long COVID, and Post-Vaccine COVID). DIAGNOSIS AND TREATMENT.

Authors:
Preprints and early-stage research may not have been peer reviewed yet.

Abstract and Figures

MANAGEMENT OF THE PATIENT WITH PERSISTENT SYMPTOMS OF COVID (CHRONIC COVID OR LONG COVID). DIAGNOSIS AND TREATMENT. In this document, the proposal for the management of patients with Persistent Symptoms of COVID (for Long COVID or Chronic COVID, and Post-Vaccine COVID) is presented in a concise manner. It is clarified that in medicine we use the term management to refer both to the part of the clinical examination, as well as to the diagnostic tests and the treatment of patients with a certain disease. When developing the management of the Persistent Symptoms of COVID, the steps to follow are presented sequentially or progressively. 6 steps are described (see Graphic). Each step would amount to an evaluation or medical consultation. In the 1st step, which would be the first clinical evaluation, one should seek to differentiate the symptoms that are caused by a Persistent Infection by SARS CoV2, from those that are not, and that may be due to other causes, such as Co-infections. , nutrient depletion and hormone deficiency, alteration in the intestinal microbiota (dysbiosis or SIBO) and other microbiota (oral, vascular, renal, pulmonary, upper respiratory, others), immune dysfunctions, sequelae and other coexisting pathologies or conditions (see at the bottom of the graph). In a separate document, the 2nd step has been developed in detail, which is the "Therapeutic Test" and the First Treatment Scheme to be indicated. The drugs and supplements included in it are shown in the attached Table as an image. The Therapeutic Plan and the 3-3-3 Treatment Scheme, which is included in the 4th step, has also been developed in detail in a separate document (an image of the Scheme Table 3-3-3 is attached). Details of the remaining steps will be published in separate documents. The main cause of Chronic COVID or Long COVID is Persistent Intracellular Infection by SARS CoV-2. There may also be persistence of viral components or particles. Regarding the "Therapeutic Test" indicated in Step 2, the first version was published in September 2020, and in April 2021 we have published a new version of this Test. Basically the change made has been the increase in the dose of IVM and the inclusion with details of the alternatives to Aspirin and IVM. In the attached image, in addition to the details of the medications and doses, the interpretation of this Test is included, which is carried out on the 7th day, at the end of its application. According to the percentage of improvement in symptoms achieved, a test result is established. If the improvement in symptoms is 40% or more, the test is POSITIVE for Persistent SARS CoV-2 Infection. If there is no improvement in symptoms, or this is only 1 to 4%, the test is NEGATIVE, so other causes must be investigated, or it may be sequelae. The% of patients who achieve a complete recovery with resolution of persistent symptoms due to SARS CoV-2 infection has been included in the Management Graph. These% are included at the end of the 2nd, 4th and 6th steps, which are the Steps in which treatments are given. Upon completing the 2nd step, the % of patients who achieve a significant improvement is between 70 and 75%. This% rises to between 80 and 85% if the 4th step is completed, this would mean that, of the 25% who did not reach recovery with the 2nd step, on average, half reach the recovery by following the treatment described in the 4th step . And if the 6th step is completed, the half of the 15 to 20% who did not make the recovery with the previous steps, will make it. As a whole, by completing the 6 steps mentioned, it is estimated that complete recovery is achieved with the eradication of the persistent infection by SARS CoV-2, in 90 to 95% of patients.
Content may be subject to copyright.
MANAGEMENT OF THE PATIENT WITH PERSISTENT SYMPTOMS OF COVID
(for Chronic COVID or Long COVID; Post-Vaccine COVID and Post-Vaccine Long COVID)
Steps to follow progressively for Diagnosis and Treatment
1st Step 3rd Step 4th Step
2nd Step 5th Step 6th Step
EVALUATION AND
CLASSIFICATION
according to the
presence and
severity of
SYMPTOMS of
HYPOPERFUSION
and HISTAMINOSIS.
Request: PCR of
cytological samples
(by centrifuged blood
and nasal brushing);
and: 1) D-Dimer,
2) Venous Blood
Gases, 3) Fibrinogen.
Assess risk of
hemorrhage.
Application of the
THERAPEUTIC TEST
with drugs against
Viral Load to assist
the diagnosis of
PERSISTENT VIRAL
INFECTION.
If there is an
improvement of 40% or
more in the symptoms,
the Test is POSITIVE,
and the treatment is
continued until 3 to 6
days after achieving a
total improvement, or
a maximum of 10 more
days (16 days in total).
Apply TREATMENT
SCHEME/Protocol 3-3-3
for Drug-Resistant Viral
Load with 3 medications
of each of the 3 Lines of
Action of the Plan. If there
Hypoperfusion moderate/
severe, is applied a 3-6-6,
6-6-9 or 6-9-9 Scheme.
If there is an improvement
>40%, continue treatment
for up to 12 days after
total improvement is
achieved or a maximum of
36 days in total.
If recovery is not
achieved, include OZONE
THERAPY and HYPER-
THERMIA with Far
Infrared Sauna o HOCTT
ELIMINATION OF VERY
PERSISTENT BIOCLOTS,
BIOFILMS AND VIRAL
LOAD applying:
1) HELP APHERESIS,
and/or another therapy
for mechanical removal
of BioClots (Partial
Exchange Transfusion
for start or other similar)
2) SCHEME/PROTOCOL
FOR MULTIDRUGS-
RESISTANT (MDR)
MICROBIAL LOAD and
undercover in BioClots,
Biofilms and Bio-
Amyloid: for months.
3) OZONOTHERAPY and
HYPERTHERMIA oHOCTT
Biofilms/ infectious foci: dental plaque, at the intestinal level, other.
Genetic defects associated with bleeding disorders.
Immune dysfunction, cytotoxicity, NK and CD8, CD4 Lymphopenia,
Low amount of neutralizing antibodies, Autoantibodies, ADE.
Sequelae: injury with loss of cells or tissues and blood vessels.
If symptoms persist:
REASSESS
SYMPTOMS OF
HYPOPERFUSION
(fatigue, brain fog,
dyspnea);
if any, perform:
Therapeutic Tests
for the diagnosis of
PERSISTENT CLOTS.
The Test is POSITIVE
if: a) Symptoms
improvement is > 30%;
and/or b) D-Dimer rises
more than 30%; and/or
c) SvO2 improves
significantly.
Reassess risk of
bleeding.
REASSESS
SYMPTOMS OF
HYPOPERFUSION,
if they persist, perform:
1) D-Dimer,
2) Venous Blood Gases,
3) Arterial Blood Gases,
4) Fibrinogen,
5) DHL-Isoenzymes,
6) Homocysteine,
7) Histamine and/or DAO,
8) Viscoelastic Test:
TEG, ROTEM, Quantra,
other, and/or Microscopy,
all for diagnosis of VERY
PERSISTENT BIOCLOTS.
Request a platelet count
and PT, to Reevaluate
the risk of hemorrhage.
Source: Aguirre-Chang, Gustavo and Trujillo, Aurora. Management of the patient with Persistent Symptoms of COVID (Chronic COVID or Long COVID). Diagnosis
and Treatment. ResearchGate. July 19, 2021.
In each Step, we must seek to identify other pathologies Not directly caused by a Persistent Infection by SARS CoV-2. It should be investigated to identify:
% of cases with sign. improvement at the end of the Step:
Coinfection/ Reactivation: Herpesvirus (EBV, HHV-6, CMV, HSV, VZV), Candida, Borrelia,
HPV, Enterovirus, Coxsackievirus, Mycoplasma, Bartonela, Rikettsiae, Babesia, etc.
Depletion of nutrients, hormones, others: Vitamins B, D, C, A, E; Zn, Mg, Ge, Se, Cu, Fe.
Dysbiosis or SIBO which causes gastrointestinal symptoms and elevation of D-Lactate.
Alteration of other Microbiomes: oral, vascular, in clots, kidneys, respirat. tract, brain,
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
1) Background: The COVID-19 pandemic lacks treatments; for this reason, the search for potential compounds against therapeutic targets is still necessary. Bioinformatics tools have allowed the rapid in silico screening of possible new metabolite candidates from natural resources or repur-posing known ones. Thus, in this work, we aimed to select phytochemical candidates from Peruvian plants with antiviral potential against three therapeutical targets of SARS-CoV-2. (2) Methods: We applied in silico technics, such as virtual screening, molecular docking, molecular dynamics simulation , and MM/GBSA estimation. (3) Results: Rutin, a compound present in Peruvian native plants, showed affinity against three targets of SARS-CoV-2. The molecular dynamics simulation demonstrated the high stability of receptor-ligand systems during the time of the simulation. Our results showed that the Mpro-Rutin system exhibited higher binding free energy than PLpro-Rutin and N-Rutin systems through MM/GBSA analysis. (4) Conclusions: Our study provides insight on natural metabolites from Peruvian plants with therapeutical potential. We found Rutin as a potential candidate with multiple pharmacological properties against SARS-CoV-2.
Article
Full-text available
Many viral infections do not have treatments or resistant to existing antiviral therapeutic interventions, and a novel strategy is required to combat virus-mediated fatalities. A novel coronavirus (coronavirus disease 2019 [COVID-19]) emerged in Wuhan, China, in late 2019 and rapidly spread across the globe. COVID-19 has impacted human society with life-threatening and unprecedented health, social, and economic issues, and it continues to affect millions of people. More than 5,800 clinical trials are in place worldwide to develop treatments to eradicate COVID-19. Historically, traditional medicine or natural products, such as medicinal plants, marine organisms and microbes, have been efficacious in treating viral infections. Nevertheless, important parameters for natural products, including clinical trial information, pharmacokinetic data, potency and toxicity profiles, in vivo and in vitro data, and product safety require validation. In this review article, an evaluation is performed of the potential application of natural product-based antiviral compounds, including crude extracts and bioactive chemical compounds obtained from medicinal plants, marine organisms, and microbes, to treat the viral infections COVID-19.
Article
Full-text available
Whereas recent investigations have revealed viral, inflammatory and vascular factors involved in SARS-CoV-2 lung pathogenesis, the pathophysiology of neurological disorders in COVID-19 remains poorly understood. Olfactory and taste dysfunction are common in COVID-19, especially in mildly symptomatic patients. Here, we conducted a virologic, molecular, and cellular study of the olfactory neuroepithelium of seven patients with COVID-19 presenting with acute loss of smell. We report evidence that the olfactory neuroepithelium may be a major site of SARS-CoV2 infection with multiple cell types, including olfactory sensory neurons, support cells, and immune cells, becoming infected. SARS-CoV-2 replication in the olfactory neuroepithelium was associated with local inflammation. Furthermore, we showed that SARS-CoV-2 induced acute anosmia and ageusia in golden Syrian hamsters, lasting as long as the virus remained in the olfactory epithelium and the olfactory bulb. Finally, olfactory mucosa sampling from patients showing long-term persistence of COVID-19-associated anosmia revealed the presence of virus transcripts and of SARS-CoV-2-infected cells, together with protracted inflammation. SARS-CoV-2 persistence and associated inflammation in the olfactory neuroepithelium may account for prolonged or relapsing symptoms of COVID-19, such as loss of smell, which should be considered for optimal medical management of this disease.
Article
Full-text available
Clinical observations indicate that COVID-19 is a systemic disease. An investigation of the viral distribution within the human body and its correlation with tissue damage can aid in understanding the pathophysiology of SARS-CoV-2 infection. We present a detailed mapping of the viral RNA in 61 tissues and organs of 11 deceased patients with COVID-19. The autopsies were performed within the early postmortem interval (between 1.5 and 15 hr, mean: 5.6 hr) to minimize the bias due to viral RNA and tissue degradation. Very high viral loads (>10 ⁴ copies/ml) were detected in most patients' lungs, and the presence of intact viral particles in the lung tissue could be verified by transmission electron microscopy. Interestingly, viral RNA was detected throughout various extrapulmonary tissues and organs without visible tissue damage. The dissemination of SARS-CoV-2-RNA throughout the body supports the hypothesis that there is a maladaptive host response with viremia and multiorgan dysfunction.
Article
Full-text available
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome corona virus-2 (SARS-CoV-2), is the most important health issue, internationally. With no specific and effective antiviral therapy for COVID-19, new or repurposed antiviral are urgently needed. Phytochemicals pose a ray of hope for human health during this pandemic, and a great deal of research is concentrated on it. Phytochemicals have been used as antiviral agents against several viruses since they could inhibit several viruses via different mechanisms of direct inhibition either at the viral entry point or the replication stages and via immunomodulation potentials. Recent evidence also suggests that some plants and its components have shown promising antiviral properties against SARS-CoV-2. This review summarizes certain phytochemical agents along with their mode of actions and potential antiviral activities against important viral pathogens. A special focus has been given on medicinal plants and their extracts as well as herbs which have shown promising results to combat SARS-CoV-2 infection and can be useful in treating patients with COVID-19 as alternatives for treatment under phytotherapy approaches during this devastating pandemic situation.
Article
Full-text available
Since the emergence of severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2) first reported in Wuhan, China in December 2019, COVID-19 has spread to all the continents at an unprecedented pace. This pandemic has caused not only hundreds of thousands of mortalities but also a huge economic setback throughout the world. Therefore, the scientific communities around the world have focused on finding antiviral therapeutic agents to either fight or halt the spread of SARS-CoV-2. Since certain medicinal plants and herbal formulae have proved to be effective in treatment of similar viral infections such as those caused by SARS and Ebola, scientists have paid more attention to natural products for effective treatment of this devastating pandemic. This review summarizes studies and ethnobotanical information on plants and their constituents used for treatment of infections caused by viruses related to the coronavirus family. Herein, we provide a critical analysis of previous reports and how to exploit published data for the discovery of novel therapeutic leads to fight against COVID-19.
Article
Full-text available
Background Ethnomedicine, a study of traditional medicine, is significant in drug discovery and development. African traditional medicine has been in existence for several thousands of years, and several drugs have been discovered and developed from it. Main text The deadly coronavirus disease 2019 (COVID-19) caused by a novel coronavirus known as SARS-CoV-2 has widely spread globally with high mortality and morbidity. Its prevention, treatment and management still pose a serious challenge. A drug for the cure of this disease is yet to be developed. The clinical management at present is based on symptomatic treatment as presented by individuals infected and this is by combination of more than two drugs such as antioxidants, anti-inflammatory, anti-pyretic, and anti-microbials. Literature search was performed through electronic searches of PubMed, Google Scholar, and several research reports including WHO technical documents and monographs. Conclusion Drug discovery from herbs is essential and should be exploited for the discovery of drugs for the management of COVID-19. This review is aimed at identifying ethnomedicinal herbs available in Africa that could be used for the discovery and development of a drug for the prevention, treatment, and management of the novel coronavirus disease 2019.
Preprint
Full-text available
Introduction: Although the efficacy of SARS-CoV-2 vaccination to prevent symptomatic COVID-19 is well established, there are no published studies on the impact on symptoms in patients with Long Covid. Anecdotal reports have suggested both a potential benefit and worsening of symptoms post vaccination with the uncertainty leading to some vaccine hesitancy amongst affected individuals. Methods: Patients initially hospitalised with COVID-19 were prospectively recruited to an observational study with clinical follow-up at 3 months (June-July 2020) and 8 months (Dec 2020-Jan 2021) post-admission. Participants who received the Pfizer-BioNTech (BNT162b2) or Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine between January to February 2021 were identified and matched 2:1 (in terms of 8-month symptoms) with participants from the same cohort who were unvaccinated. All were re-assessed at 1 month post vaccination (or matched timepoint for unvaccinated cohort). Validated quality of life (SF-36), mental wellbeing (WEMWBS) and ongoing symptoms were assessed at all timepoints. Formal statistical analysis compared the effect of vaccination on recent quality of life using baseline symptoms, age, and gender in linear regression. Results: Forty-four vaccinated participants were assessed at a median of 32 days (IQR 20-41) post vaccination with 22 matched unvaccinated participants. Most were highly symptomatic of Long Covid at 8 months (82% in both groups had at least 1 persistent symptom), with fatigue (61%), breathlessness (50%) and insomnia (38%) predominating. There was no significant worsening in quality-of-life or mental wellbeing metrics pre versus post vaccination. Nearly two-thirds (n=27) reported transient (<72hr duration) systemic effects (including fever, myalgia and headache). When compared to matched unvaccinated participants from the same cohort, those who had receive a vaccine had a small overall improvement in Long Covid symptoms, with a decrease in worsening symptoms (5.6% vaccinated vs 14.2% unvaccinated) and increase in symptom resolution (23.2% vaccinated vs 15.4% unvaccinated) (p=0.035). No difference in response was identified between Pfizer-BioNTech or Oxford-AstraZeneca vaccines. Conclusions: Receipt of vaccination with either an mRNA or adenoviral vector vaccine was not associated with a worsening of Long Covid symptoms, quality of life, or mental wellbeing. Individuals with prolonged COVID-19 symptoms should receive vaccinations as suggested by national guidance.
Article
In 2020, a novel strain of coronavirus (COVID-19) has led to a significant morbidity and mortality worldwide. As of the date of this writing, a total of 116 M cases has been diagnosed worldwide leading to 2.5 M deaths. The number of mortalities is directly correlated with the rise of innate immune cells (especially macrophages) in the lungs that secrete inflammatory cytokines (IL-1β and IL-6) leading to the development of "Cytokine Storm Syndrome" (CSS), multi-organ-failure and death. Given that currently the treatment of this condition is rare and release of effective vaccine might be months away, here, we review the plants and their pharmacologically active-compounds as potential phytopharmaceuticals for the virus induced inflammatory response. Experimental validation of the effectiveness of these natural compounds to prevent or reduce the cytokine storm might be beneficial as an adjunct treatment of SARS-CoV-2.